Cardiovascular events in cancer patients treated with highly or moderately emetogenic chemotherapy: results from a population-based study.

Journal of Cancer Epidemiology
Thao T Vo, Jeanenne J Nelson

Abstract

Studies on cardiovascular safety in cancer patients treated with highly or moderately emetogenic chemotherapy (HEC or MEC), who may have taken the antiemetic, aprepitant, have been limited to clinical trials and postmarketing spontaneous reports. Our study explored background rates of cardiovascular disease (CVD) events among HEC- or MEC-treated cancer patients in a population-based setting to contextualize events seen in a new drug development program and to determine at a high level whether rates differed by aprepitant usage. Medical and pharmacy claims data from the 2005-2007 IMPACT National Benchmark Database were classified into emetogenic chemotherapy categories and CVD outcomes. Among 5827 HEC/MEC-treated patients, frequencies were highest for hypertension (16-21%) and composites of venous (7-12%) and arterial thromboembolic events (4-7%). Aprepitant users generally did not experience higher frequencies of events compared to nonusers. Our study serves as a useful benchmark of background CVD event rates in a population-based setting of cancer patients.

References

Feb 1, 2000·Journal of the History of the Behavioral Sciences·I Verstegen
Mar 31, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M F De MarcoJ W Coebergh
May 2, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·V B Pai, M C Nahata
Aug 19, 2003·The Annals of Pharmacotherapy·Rudolph M Navari, Jim M Koeller
Dec 16, 2004·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Steven M GrunbergMaurizio Tonato
Apr 20, 2005·Cancer Chemotherapy and Pharmacology·Milly E de JongeSjoerd Rodenhuis
Jun 9, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·David G WarrKevin J Horgan
Jun 23, 2005·Current Medical Research and Opinion·Matti Aapro
Sep 24, 2005·Advances in Health Sciences Education : Theory and Practice
Aug 31, 2006·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Enzo BallatoriRobert R Deuson
Mar 17, 2009·Expert Opinion on Pharmacotherapy·Rudolph M Navari
Jun 13, 2009·Journal of the American College of Cardiology·Edward T H Yeh, Courtney L Bickford
Sep 2, 2009·Drugs·Monique P Curran, Dean M Robinson
Nov 26, 2009·Expert Opinion on Drug Metabolism & Toxicology·Kamalesh K SankhalaSant P Chawla
Dec 19, 2009·Circulation·UNKNOWN WRITING GROUP MEMBERSUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Apr 20, 2010·International Journal of Cardiology·Jean-Jacques MonsuezJean-Yves Artigou
Mar 23, 2011·Expert Opinion on Drug Safety·Christina H Ruhlmann, Jørn Herrstedt

❮ Previous
Next ❯

Citations

May 5, 2016·Critical Reviews in Oncology/hematology·Sandro BarniMary Cabiddu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.